NDD Medical Technologies is a pioneering company in the field of pulmonary function testing, driven by a vision to revolutionize lung health diagnostics through innovative ultrasound technology. The company's journey began with the groundbreaking work of Dr. Karl Harnoncourt and Dr. Christian Buess, who recognized the potential of ultrasound in measuring lung function with unparalleled precision.

In the 1980s, Dr. Karl Harnoncourt, a cardio-pulmonologist, observed a significant gap in the diagnostic capabilities for pulmonary diseases compared to cardiology. Simultaneously, Dr. Christian Buess, while completing his dissertation at the Swiss Federal Institute of Technology (ETH Zurich), demonstrated the feasibility of using ultrasound technology to measure the speed and composition of respiratory gases accurately. Their paths crossed through a collaborative study with scientists from the Max Planck Institute in Göttingen, leading to the formation of ndd Medizintechnik AG in 1996, now known as ndd Medical Technologies.

NDD Medical Technologies is committed to enhancing lung health through early diagnosis and accurate treatment of chronic lung diseases such as Chronic Obstructive Pulmonary Disease (COPD). For over 25 years, the company has been at the forefront of developing innovative Pulmonary Function Testing (PFT) devices. Their EasyOne product line is designed to provide physicians with reliable diagnostic tools at the point of care, enabling immediate treatment and preventing irreversible lung damage. This mission is supported by ongoing research, awareness campaigns, and the global availability of their products in over 100 countries.

The company's vision is to improve lung health worldwide by promoting early diagnosis and treatment of respiratory diseases. With an estimated 235 million people suffering from respiratory symptoms, many of whom remain undiagnosed or misdiagnosed, ndd Medical Technologies aims to bridge this gap. They advocate for increased awareness and education about respiratory diseases and collaborate with healthcare providers, non-profit organizations, and lung disease specialists to achieve this goal. Their innovative approach to spirometry and advanced lung function testing, including Diffusing Capacity for Carbon Monoxide (DLCO testing) and Multi-Breath Washout (MBW testing), is crucial in achieving accurate diagnoses and better patient outcomes.